Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial. - Université de Lille
Article Dans Une Revue The Lancet Gastroenterology & Hepatology Année : 2024

Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.

Nadia Ovchinsky
  • Fonction : Auteur
Alastair Baker
  • Fonction : Auteur
Ulrich Baumann
  • Fonction : Auteur
Philip Bufler
  • Fonction : Auteur
Mara Cananzi
  • Fonction : Auteur
Piotr Czubkowski
  • Fonction : Auteur
Özlem Durmaz
  • Fonction : Auteur
Ryan Fischer
  • Fonction : Auteur
Guiseppe Indolfi
  • Fonction : Auteur
Wikrom W. Karnsakul
  • Fonction : Auteur
Way S. Lee
  • Fonction : Auteur
Guiseppe Maggiore
  • Fonction : Auteur
Philip Rosenthal
  • Fonction : Auteur
Etienne Sokal
  • Fonction : Auteur
Ekkehard Sturm
  • Fonction : Auteur
Wendy van der Woerd
  • Fonction : Auteur
Henkjan J Verkade
  • Fonction : Auteur
Andrew Wehrman
  • Fonction : Auteur
Christine Clemson
  • Fonction : Auteur
Qifeng Yu
  • Fonction : Auteur
Quanhong Ni
  • Fonction : Auteur
Jessica Ruvido
  • Fonction : Auteur
Susan Manganaro
  • Fonction : Auteur
Jan P. Mattsson
  • Fonction : Auteur

Résumé

Background In patients with Alagille syndrome, cholestasis-associated clinical features can include high serum bile acids and severe pruritus that can necessitate liver transplantation. We aimed to evaluate the efficacy and safety of the ileal bile acid transporter inhibitor odevixibat versus placebo in patients with Alagille syndrome. Methods The ASSERT study was a phase 3, double-blind, randomised, placebo-controlled trial that enrolled patients at 21 medical centres or hospitals in ten countries (Belgium, France, Germany, Italy, Malaysia, the Netherlands, Poland, Türkiye, the UK, and the USA). Eligible patients had a genetically confirmed diagnosis of Alagille syndrome, a history of significant pruritus, and elevated serum bile acids. Patients were randomly assigned (2:1) to receive oral odevixibat 120 μg/kg per day or placebo for 24 weeks (in a block size of six and stratified by age: <10 years and ≥10 years to <18 years) via a web-based system. Patients, clinicians, study staff, and people analysing the data were masked to treatment allocation. The primary efficacy endpoint was change in caregiver-reported scratching score (on the PRUCISION instrument; range 0–4) from baseline to weeks 21–24. The prespecified key secondary efficacy endpoint was change in serum bile acid concentration from baseline to the average of weeks 20 and 24. Outcomes were analysed in patients who received at least one dose of study drug (the full analysis set for efficacy outcomes and the safety analysis set for safety outcomes). This trial is registered on ClinicalTrials.gov (NCT04674761) and EudraCT (2020-004011-28), and is completed. Findings Between Feb 26, 2021, and Sept 9, 2022, 52 patients were randomly assigned to receive odevixibat (n=35) or placebo (n=17), all of whom were included in the analysis sets. The median age was 5·5 years (IQR 3·2 to 8·9). 27 (52%) of 52 patients were male and 25 (48%) were female. The mean scratching score was elevated at baseline in both groups (2·8 [SD 0·5] for odevixibat vs 3·0 [0·6] for placebo). Mean scratching scores at weeks 21–24 were 1·1 (0·9) for odevixibat and 2·2 (1·0) for placebo, representing a least-squares (LS) mean change of –1·7 (95% CI –2·0 to –1·3) for odevixibat and –0·8 (–1·3 to –0·3) for placebo, which was significantly greater for odevixibat than for placebo (difference in LS mean change from baseline –0·9 [95% CI –1·4 to –0·3]; p=0·0024). Odevixibat also resulted in significantly greater reductions in mean serum bile acids from baseline versus placebo (237 μmol/L [SD 115] with odevixibat vs 246 μmol/L [121] with placebo) to the average of weeks 20 and 24 (149 μmol/L [102] vs 271 μmol/L [167]; LS mean change –90 μmol/L [95% CI –133 to –48] with odevixibat vs 22 μmol/L [–35 to 80] with placebo; difference in LS mean change –113 μmol/L [95% CI –179 to –47]; p=0·0012). The most common treatment-emergent adverse events were diarrhoea (ten [29%] of 35 patients in the odevixibat group vs one [6%] of 17 in the placebo group) and pyrexia (eight [23%] vs four [24%]). Seven patients had serious treatment-emergent adverse events during the treatment period: five (14%) in the odevixibat group and two (12%) in the placebo group. No patients discontinued treatment and there were no deaths. Interpretation Odevixibat could be an efficacious non-surgical intervention to improve pruritus, reduce serum bile acids, and enhance the standard of care in patients with Alagille syndrome. Longer-term safety and efficacy data of odevixibat in this population are awaited from the ongoing, open-label ASSERT-EXT study. Funding Albireo Pharma, an Ipsen company.
Fichier principal
Vignette du fichier
PIIS2468125324000748.pdf (460.2 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04678045 , version 1 (26-08-2024)

Licence

Identifiants

Citer

Nadia Ovchinsky, Madeleine Aumar, Alastair Baker, Ulrich Baumann, Philip Bufler, et al.. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.. The Lancet Gastroenterology & Hepatology, 2024, The Lancet Gastroenterology & Hepatology, 9, pp.P632-645. ⟨10.1016/S2468-1253(24)00074-8⟩. ⟨hal-04678045⟩
9 Consultations
1 Téléchargements

Altmetric

Partager

More